About: Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 September 2000

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована у вересні 2000 (uk) im September 2000 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en setiembre de 2000 (ast) scientific article published on 01 September 2000 (en)
publication date	wds:Q74352469-2377F573-4A23-4A5D-9C0A-4FB9366ED49E
publication date	2000-09-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q74352469-C01BBB8C-ED94-4C0A-8009-6AC48083130C
language of work or name	English
author name string	wds:Q74352469-151CBB5B-E67E-4358-8F29-D8A841633BD4 wds:Q74352469-1BCFF700-3909-42BF-BAEC-720B75738997 wds:Q74352469-2400777E-FEB3-4BFD-BF9F-0B9249FE437A wds:Q74352469-3C14B8C0-4640-44A3-A5DF-7581843215DF wds:Q74352469-66D13BBB-F1CC-48D7-979F-FBC106F75777 wds:Q74352469-A8548B3C-8B09-44EE-BF41-BB9C696A9770 wds:Q74352469-A8C59510-3409-4C93-A99A-BE3D5DF66F7E wds:Q74352469-C2ED724D-DD56-460A-B4B7-F9DAA1E43314 wds:Q74352469-E5EFC9B0-3A50-4782-9C49-9494F66A8BD0 wds:Q74352469-F90032E9-E2E1-41B7-82EF-6BF9138EE1B5 wds:Q74352469-F9074A40-9478-49CF-A74E-C210A465FFB2
author name string	Wu M Ross PD Wasnich RD Bone HG Meunier PJ Menkes CJ Desai R Santora AC Emkey R Rodriguez-Portales JA Tonino RP
rdfs:label	Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group (en) Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group (nl)
skos:prefLabel	Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group (en) Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group (nl)
name	Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group (en) Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group (nl)
title	wds:Q74352469-A0A3C760-8595-4015-A4EA-BAC39EBE3C06
title	Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group (en)
page(s)	wds:Q74352469-F8C73DD6-A16F-45E7-B998-3FA19A78F31A
page(s)	3109-3115
instance of	wds:Q74352469-5D4D0B3F-C671-47A9-BA0E-43612EB1C113
instance of	scholarly article
PubMed ID	wds:Q74352469-07B59183-432C-4190-B634-80709EA397B5
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/10999794
PubMed ID	10999794
published in	wds:Q74352469-07DB51E6-58EE-4192-9823-57D9CA5F2679
published in	The Journal of Clinical Endocrinology and Metabolism
issue	wds:Q74352469-04474422-33BF-4235-8ACA-9C033CEC3B90
volume	wds:Q74352469-C30CC747-C604-4BEC-A1AB-E738AB3C737D
issue	9
volume	85
DOI	wds:Q74352469-C004E984-0DFB-47F8-9FC5-E99183B6545F
DOI	http://dx.doi.org/10.1210/JCEM.85.9.6777
DOI	10.1210/JCEM.85.9.6777
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q74352469
is cites work of	Bisphosphonate mechanism of action Bone quality: where do we go from here? Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries--an economic evaluation based on the fracture intervention trial Effects of alendronate and calcitonin on bone mineral density in postmenopausal osteoporotic women. An observational study Femoral insufficiency fractures associated with prolonged bisphosphonate therapy Incidence and bone biopsy findings of atypical femoral fractures. Use of bisphosphonates for the treatment of stress fractures in athletes Persistence, reproducibility, and cost-effectiveness of an intervention to improve the quality of osteoporosis care after a fracture of the wrist: results of a controlled trial Regional bone metabolism at the lumbar spine and hip following discontinuation of alendronate and risedronate treatment in postmenopausal women. Cost-effectiveness of a multifaceted intervention to improve quality of osteoporosis care after wrist fracture. Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective Combined Treatment with Vitamin K2and Bisphosphonate in Postmenopausal Women with Osteoporosis Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats Ulnar fractures with bisphosphonate therapy: a systematic review of published case reports Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis Three-year effectiveness of intravenous pamidronate versus pamidronate plus slow-release sodium fluoride for postmenopausal osteoporosis We need a break: Bisphosphonates Association between alendronate and atypical femur fractures: a meta-analysis Case reports: two femoral insufficiency fractures after long-term alendronate therapy Bilateral atypical insufficiency fractures of the proximal tibia and a unilateral distal femoral fracture associated with long-term intravenous bisphosphonate therapy: a case report Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis Effects of combination treatment with alendronate and vitamin K(2) on bone mineral density and strength in ovariectomized mice Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Reduced osteoclastogenesis and RANKL expression in marrow from women taking alendronate Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer Alendronate treatment improves bone-pedicle screw interface fixation in posterior lateral spine fusion: an experimental study in a porcine model Bisphosphonates in osteoporosis Canadian Consensus Conference on osteoporosis, 2006 update. Theoretical analysis of alendronate and risedronate effects on canine vertebral remodeling and microdamage Implant failure caused by non-union of bisphosphonate-associated subtrochanteric femur fracture NCCN Task Force Report: Bone Health in Cancer Care Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study Bisphosphonate increases risk of gastroduodenal ulcer in rheumatoid arthritis patients on long-term nonsteroidal antiinflammatory drug therapy Progress in osteoporosis and fracture prevention: focus on postmenopausal women Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women Alendronate in the prevention of osteoporosis: 7-year follow-up Fracture risk associated with continuation versus discontinuation of bisphosphonates after 5 years of therapy in patients with primary osteoporosis: a systematic review and meta-analysis

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 194 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software